Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03708289
Other study ID # UZB BONBO
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date September 2016
Est. completion date October 2018

Study information

Verified date September 2016
Source Universitair Ziekenhuis Brussel
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Improved survival of people living with HIV has resulted in an increased occurrence of other comorbidities, such as cardiovascular, renal, bone and endocrine pathologies.

The data that is currently available on cART-associated changes in bone mineral density, body composition and hormonal values is short-term and mainly derived from patients initiating cART in accordance with previous treatment guidelines. As current guidelines recommend earlier cART initiation and as PI-based regimens are becoming less frequently used, a favorable outcome on bone health, body composition measures and endocrine status might be expected.

This study will therefore prospectively document alterations in bone mineral density, body composition and endocrine status in HIV-infected patients in whom, in the current treatment era, an INSTI-based cART regimen is initiated as a first line regimen.


Description:

Patients will be included at the initiation of cART. The follow up for this study is planned to fit within the routine follow up consultations and includes some extra experimental investigations, such as the medical body composition measurements, resting energy expenditure measurement, Achilles bone ultrasonometer and DXA scans. Standard blood and urine samples will be taken, including standard analyses and some extra analyses for the study.

Physical activity will be monitored for 5 consecutive days using a bracelet device while patients will be asked to record their food intake using a standardized diet agenda.

Total follow up time will be 144 weeks and includes 12 visits in total.


Recruitment information / eligibility

Status Terminated
Enrollment 120
Est. completion date October 2018
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Documented and confirmed HIV-1-infection

- Aged 18 years or above

- Naïve to anti-retroviral treatment, unless anti-retrovirals were taken in the context of occupational or non-occupational post-exposure prophylaxis or in the context of prevention of mother-to-child transmission

- Willingness to sign the written informed consent

Exclusion Criteria:

- Pregnancy and breastfeeding

- Patients receiving medical care through an 'emergency care package'

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
DXA scan
total and hip and spine dual energy x-ray absorptiometry
Other:
Achilles bone US

Medical body composition measurements

Resting energy expenditure measurement


Locations

Country Name City State
Belgium UZ Brussel Jette

Sponsors (1)

Lead Sponsor Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of changes in BMD from baseline 144 weeks of follow-up
Primary Assessment of changes in trunk fat from baseline 144 weeks of follow-up
Primary Determination of the incidence of subclinical and clinical hypothyroidism Within 144 weeks of follow-up
Secondary Correlation between T-scores obtained by Achilles bone ultrasonometer (screening tool) and hip and spine DXA scan (gold standard) 144 weeks of follow-up
Secondary Correlations between changes in body composition and endocrine values 144 weeks of follow-up
Secondary Correlation between changes in VAT and trunk fat and changes in waist circumference 144 weeks of follow-up
Secondary Description of changes in body composition in relation to the resting energy expenditure 144 weeks of follow-up
See also
  Status Clinical Trial Phase
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Completed NCT02547844 - Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla Phase 4
Terminated NCT01345630 - Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 Phase 3
Completed NCT00807443 - Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 Phase 2
Terminated NCT01173276 - Intrauterine Insemination In HIV-Discordant Couples N/A
Completed NCT01140139 - Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions Phase 1
Withdrawn NCT00340223 - HLA-B35 Alleles and AIDS N/A
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT02217904 - A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) Phase 1
Completed NCT00772902 - ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Phase 4
Completed NCT04006704 - Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets Phase 1
Terminated NCT03060629 - A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa Phase 2
Recruiting NCT00981695 - Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers Phase 1/Phase 2
Completed NCT00982579 - Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers Phase 1
Completed NCT01084343 - Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects Phase 1
Completed NCT00665847 - TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents Phase 2
Completed NCT00098293 - Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine Phase 3
Completed NCT05944848 - A Study of CL-197 Capsules in Healthy Participants Phase 1
Completed NCT00479999 - Phase 1 Safety Study of Two Experimental HIV Vaccines Phase 1
Completed NCT01274780 - Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients Phase 4